These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21054260)

  • 41. The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.
    Snider SE; Vunck SA; van den Oord EJ; Adkins DE; McClay JL; Beardsley PM
    Eur J Pharmacol; 2012 Mar; 679(1-3):75-80. PubMed ID: 22306241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone.
    Chiu CT; Ma T; Ho IK
    Brain Res Bull; 2005 Sep; 67(1-2):100-9. PubMed ID: 16140168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Approaches to the development of medications for the treatment of methamphetamine dependence.
    Vocci FJ; Appel NM
    Addiction; 2007 Apr; 102 Suppl 1():96-106. PubMed ID: 17493058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sigma receptors and cocaine abuse.
    Narayanan S; Mesangeau C; Poupaert JH; McCurdy CR
    Curr Top Med Chem; 2011; 11(9):1128-50. PubMed ID: 21050176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. l-Scoulerine attenuates behavioural changes induced by methamphetamine in zebrafish and mice.
    Mi G; Gao Y; Yan H; Jin X; Ye E; Liu S; Gong Z; Yang H; Yang Z
    Behav Brain Res; 2016 Feb; 298(Pt A):97-104. PubMed ID: 26433144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutual enhancement of central neurotoxicity induced by ketamine followed by methamphetamine.
    Ke JJ; Chen HI; Jen CJ; Kuo YM; Cherng CG; Tsai YP; Ho MC; Tsai CW; Yu L
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):239-47. PubMed ID: 18076959
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurotoxicity of methamphetamine: Main effects and mechanisms.
    Jayanthi S; Daiwile AP; Cadet JL
    Exp Neurol; 2021 Oct; 344():113795. PubMed ID: 34186102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Melatonin Attenuates Methamphetamine-Induced Neurotoxicity.
    Wongprayoon P; Govitrapong P
    Curr Pharm Des; 2016; 22(8):1022-32. PubMed ID: 25248807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors.
    Brammer MK; Gilmore DL; Matsumoto RR
    Eur J Pharmacol; 2006 Dec; 553(1-3):141-5. PubMed ID: 17070798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Spontaneous recrudescence of psychotic diseases caused by methamphetamine (a stimulant): the stress type and the role of noradrenaline and dopamine systems].
    Aburai K; Ikemoto U; Goto K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):319-20. PubMed ID: 15658512
    [No Abstract]   [Full Text] [Related]  

  • 51. Methods in drug abuse models: comparison of different models of methamphetamine paradigms.
    Kobeissy FH; Mitzelfelt JD; Fishman I; Morgan D; Gaskins R; Zhang Z; Gold MS; Wang KK
    Methods Mol Biol; 2012; 829():269-78. PubMed ID: 22231820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals.
    Hashimoto K; Ishiwata K
    Curr Pharm Des; 2006; 12(30):3857-76. PubMed ID: 17073684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users.
    Kim DJ; Roh S; Kim Y; Yoon SJ; Lee HK; Han CS; Kim YK
    Neurosci Lett; 2005 Nov; 388(2):112-5. PubMed ID: 16039058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methamphetamine: geographic areas and populations at risk, and emerging evidence for effective interventions.
    Degenhardt L; Baker A; Maher L
    Drug Alcohol Rev; 2008 May; 27(3):217-9. PubMed ID: 18368601
    [No Abstract]   [Full Text] [Related]  

  • 55. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction.
    Li MD; Wang J; Niu T; Ma JZ; Seneviratne C; Ait-Daoud N; Saadvandi J; Morris R; Weiss D; Campbell J; Haning W; Mawhinney DJ; Weis D; McCann M; Stock C; Kahn R; Iturriaga E; Yu E; Elkashef A; Johnson BA
    BMC Med Genomics; 2014 Dec; 7():65. PubMed ID: 25495887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurotoxicity Induced by Mephedrone: An up-to-date Review.
    Pantano F; Tittarelli R; Mannocchi G; Pacifici R; di Luca A; Busardò FP; Marinelli E
    Curr Neuropharmacol; 2017; 15(5):738-749. PubMed ID: 27908258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of methamphetamine neurotoxicity in forensic autopsy cases.
    Kitamura O
    Leg Med (Tokyo); 2009 Apr; 11 Suppl 1():S63-5. PubMed ID: 19269222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51.
    Sharma HS; Sjöquist PO; Ali SF
    Curr Pharm Des; 2007; 13(18):1903-23. PubMed ID: 17584116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genes and molecules that can potentiate or attenuate psychostimulant dependence: relevance of data from animal models to human addiction.
    Niwa M; Yan Y; Nabeshima T
    Ann N Y Acad Sci; 2008 Oct; 1141():76-95. PubMed ID: 18991952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The need for speed: an update on methamphetamine addiction.
    Barr AM; Panenka WJ; MacEwan GW; Thornton AE; Lang DJ; Honer WG; Lecomte T
    J Psychiatry Neurosci; 2006 Sep; 31(5):301-13. PubMed ID: 16951733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.